Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial
Smolen, J S, Emery, P, Ferraccioli, G F, Samborski, W, Berenbaum, F, Davies, O R, Koetse, W, Purcaru, O, Bennett, B, Burkhardt, H
Published in Annals of the rheumatic diseases (01.05.2015)
Published in Annals of the rheumatic diseases (01.05.2015)
Get full text
Journal Article
Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis
Furst, D. E., Shaikh, S. A., Greenwald, M., Bennett, B., Davies, O., Luijtens, K., Staelens, F., Koetse, W., Bertin, P.
Published in Arthritis care & research (2010) (01.02.2015)
Published in Arthritis care & research (2010) (01.02.2015)
Get full text
Journal Article
FRI0002 Pharmacodynamic Effects of the CD22-Targeted Monoclonal Antibody Epratuzumab on B Cells in Cynomolgus Monkeys and in Patients with Systemic Lupus Erythematosus
Shock, A., Kilgallen, B., Koetse, W., Stach, C., Bongardt, S., Galateanu, C., Brackenbury, L., Williams, N., Wolfreys, A.
Published in Annals of the rheumatic diseases (01.06.2015)
Published in Annals of the rheumatic diseases (01.06.2015)
Get full text
Journal Article
THU0023 Correlation of Laboratory and Clinical Parameters with British Isles Lupus Assessment Group Response in an Open-Label Extension Study of Epratuzumab in Systemic Lupus Erythematosus
Furie, R.A., Petri, M., Gordon, C., Strand, V., Galateanu, C., Bongardt, S., Koetse, W., Wallace, D.J.
Published in Annals of the rheumatic diseases (01.06.2014)
Published in Annals of the rheumatic diseases (01.06.2014)
Get full text
Journal Article
FRI0150 Maintenance of remission in rheumatoid arthritis patients with low-moderate disease activity following withdrawal of certolizumab PEGOL treatment: Week 52 results from the certain study
Smolen, J.S., Emery, P., Ferraccioli, G., Samborski, W., Berenbaum, F., Davies, O., Koetse, W., Bennett, B., Burkhardt, H.
Published in Annals of the rheumatic diseases (01.06.2013)
Published in Annals of the rheumatic diseases (01.06.2013)
Get full text
Journal Article
SAT0126 Evaluation of two dosing regimens of certolizumab pegol for maintenance of clinical response in patients with active rheumatoid arthritis: Primary results from doseflex, a phase IIIB study
Furst, D.E., Shaikh, S.A., Greenwald, M., Bennett, B., Staelens, F., Koetse, W., Bertin, P.
Published in Annals of the rheumatic diseases (01.06.2013)
Published in Annals of the rheumatic diseases (01.06.2013)
Get full text
Journal Article
FRI0004 Randomization to Patient-Reported RAPID3 versus Physician-Based CDAI Tools for Prediction of Treatment Response and Assessment of Patient-Reported Outcomes in Rheumatoid Arthritis Patients Receiving Certolizumab Pegol: Results from the PREDICT Study
Curtis, J.R., Churchill, M., Kivitz, A., Samad, A., Gauer, L., Coteur, G., Gervitz, L., Koetse, W., Melin, J., Yazici, Y.
Published in Annals of the rheumatic diseases (01.06.2014)
Published in Annals of the rheumatic diseases (01.06.2014)
Get full text
Journal Article
POS1023 LONG-TERM SAFETY OF RISANKIZUMAB IN PATIENTS WITH PSORIATIC DISEASE: FINDINGS FROM INTEGRATED ANALYSES OF 17 CLINICAL TRIALS IN PSORIASIS AND 4 IN PSORIATIC ARTHRITIS
Gordon, K. B., Blauvelt, A., Bachelez, H., Kaplan, B., Koetse, W., Drogaris, L., Sinvhal, R., Papp, K.
Published in Annals of the rheumatic diseases (01.06.2022)
Published in Annals of the rheumatic diseases (01.06.2022)
Get full text
Journal Article